Xenon Pharmaceuticals (XENE) Capital Expenditures (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Capital Expenditures of $133000.0 for Q1 2026, up 209.3% year-over-year from $43000.0 in Q1 2025, and down 58.18% quarter-over-quarter from $318000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Capital Expenditures (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Capital Expenditures for 14 consecutive years, with $133000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 209.3% year-over-year to $133000.0; the TTM figure through Mar 2026 stood at $889000.0 (down 69.66% YoY), while the FY2025 annual figure was $799000.0, down 74.02% from the prior year.
- Capital Expenditures fell to $133000.0 in Q1 2026 per XENE's latest filing, from $318000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.2 million in Q1 2023 and bottomed at $43000.0 in Q1 2025.
- Historically, Capital Expenditures has averaged $736352.9 across 5 years, with a median of $386000.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 940.57% in 2023 and fell as far as 95.55% in 2023.
- Xenon Pharmaceuticals' Capital Expenditures stood at $1.8 million in 2022, then plunged by 95.55% to $78000.0 in 2023, then surged by 903.85% to $783000.0 in 2024, then plunged by 59.39% to $318000.0 in 2025, then plunged by 58.18% to $133000.0 in 2026.
- Business Quant data shows XENE's Capital Expenditures at $133000.0 in Q1 2026, $318000.0 in Q4 2025, and $281000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 275,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 275,000.00 |
| Jun 30, 2026 | 275,000.00 |
| Mar 31, 2026 | 133,000.00 |
| Mar 31, 2026 | 133,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 783,000.00 |
| Dec 31, 2024 | 783,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Mar 31, 2024 | 188,000.00 |
| Mar 31, 2024 | 188,000.00 |